Miniaturized high-throughput transcriptomics for preclinical drug discovery
23 Jun 2023

Biopharmaceutical companies utilize high-throughput drug screens to understand targets of regulators in biological processes and to identify new pre-clinical lead molecules. Utilizing DRUG-Seq to generate large-scale RNA sequencing data may accelerate pharmacological profiling – including mechanisms of action and off-target profiling – of compound libraries.

In this expert-led webinar, Ian Shoemaker and Kelly Parliament from Beckman Coulter Life Sciences share how innovative acoustic liquid handler technology can help to accelerate throughput while simultaneously reducing costs when miniaturizing the drug screening process. Here, they highlight the Echo 655T, an acoustic liquid handler that enables miniaturization of the drug screening process through rapid and accurate transfer of compounds without the use of plastic tips.

Our speakers will also explain how bulk RNA barcoding and sequencing (BRB-seq) enables the use of high-throughput RNA library preparation and sequencing by drastically reducing price and preparation time. Plus, discover how you can save time and cost utilizing the MERCURIUS™ Cell Lysate BRB-seq Library Preparation kit and how the entire automated BRB-seq workflow, from cell lysis to sequencing-ready DNA libraries, can be completed on the Biomek i7 dual hybrid workstation.

Key learning objectives

  • Discover how DRUG-Seq can be used to generate large-scale RNA sequencing data that may accelerate pharmacological profiling of the compound library
  • Learn about the combined DRUG-Seq workflow of miniatured high-throughput drug screening and transcriptomics using the Echo 655T acoustic liquid handler and the Biomek i7 Automated Workstation

Who should attend?

  • Lab directors and managers in preclinical drug screening and next-generation sequencing
  • Research professionals interested in transcriptomic profiling and automation

Certificate of attendance

webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Beckman Coulter Life Sciences